gadofosveset trisodium (MS 325)

a low molecular weight molecule chelated to Gadolinium, that strongly binds to plasma proteins; Vasovist is an injectable for imaging the vascular system by magnetic resonance angiography

Also Known As:

Networked: 108 relevant articles (14 outcomes, 32 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Hamm, Bernd: 6 articles (10/2021 - 07/2009)
2.	Makowski, Marcus R: 6 articles (10/2021 - 09/2011)
3.	Shamsi, Kohkan: 6 articles (01/2008 - 12/2003)
4.	Botnar, Rene M: 5 articles (10/2021 - 01/2019)
5.	Essig, Marco: 5 articles (01/2016 - 03/2007)
6.	Beets-Tan, Regina G H: 5 articles (08/2014 - 03/2011)
7.	Leiner, Tim: 5 articles (01/2012 - 03/2007)
8.	Goyen, Mathias: 5 articles (01/2008 - 08/2002)
9.	Botnar, René M: 4 articles (01/2018 - 09/2011)
10.	Beets, Geerard L: 4 articles (08/2014 - 03/2011)

Related Diseases

1.	Pathologic Constriction (Stenosis) 07/01/2009 - "The quantification and detection of arterial stenosis is improved by the steady state high-resolution gadofosveset trisodium-enhanced MR angiography. " 07/01/2005 - "Gadofosveset-enhanced MR angiography showed significant improvement (P < .001) compared with unenhanced MR angiography for each of the readers for diagnosis of clinically significant (> or = 50%) stenosis. " 04/01/2007 - "All readers found fewer images uninterpretable with Vasovist enhancement and the agreement regarding stenosis location and degree of stenosis between MR angiography and DSA improved substantially after Vasovist administration compared to the noncontrast examination. " 01/01/2020 - "Segments containing lesions with a QFR <0.8 (n = 9) were associated with significantly higher signal enhancement on Gadofosveset-enhanced CMR as compared to segments containing a lesions without significant stenosis (lesion-QFR>0.8; n = 19) (5.32 (4.47-7.02) vs. 2.42 (1.04-5.11); p = 0.042). " 03/01/2009 - "The overall sensitivity, specificity, and accuracy of i.v. gadofosveset-enhanced MR angiography for characterization of clinically significant stenosis and occlusion were 91.4%, 96.1%, and 93.9%. "
2.	Vascular Diseases (Vascular Disease) 11/01/2006 - "Subjects with known or suspected vascular disease were administered 0.03 mmol/kg gadofosveset (767 subjects) or placebo (49 subjects) in phase II and phase III studies. " 06/01/2013 - "Because of its prolonged intravascular residence time, gadofosveset trisodium is particularly useful for evaluating venous, dynamic, and functional vascular disease with a single low-dose contrast injection." 01/01/2007 - "The clinical trials demonstrate that gadofosveset-enhanced magentic resonance angiography is: safe and well tolerated in patients with vascular disease; effective for the detection of vascular stenosis and aneurysms; significantly more accurate (both more sensitive and specific) than noncontrast magnetic resonance angiography for the diagnosis of vascular stenoses; and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization." 02/01/2006 - "The clinical trials show that Vasovist-enhanced MR angiography is safe and well-tolerated in patients with vascular disease, effective for the detection of vascular stenosis and aneurysms, significantly more accurate (both more sensitive and specific) than non-contrast MR angiography for the diagnosis of vascular stenoses, and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization." 01/01/2008 - "Prior to approval, gadofosveset underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials show that gadofosveset-enhanced magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular disease and effective for the detection of vascular stenosis and aneurysms gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds."
3.	Aneurysm (Aneurysms) 10/01/2012 - "Fourteen patients with a nonshrinking aneurysm without endoleak on computed tomography/computed tomography angiography underwent MRI with a blood pool agent (gadofosveset trisodium). " 01/01/2007 - "The clinical trials demonstrate that gadofosveset-enhanced magentic resonance angiography is: safe and well tolerated in patients with vascular disease; effective for the detection of vascular stenosis and aneurysms; significantly more accurate (both more sensitive and specific) than noncontrast magnetic resonance angiography for the diagnosis of vascular stenoses; and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization." 02/01/2006 - "The clinical trials show that Vasovist-enhanced MR angiography is safe and well-tolerated in patients with vascular disease, effective for the detection of vascular stenosis and aneurysms, significantly more accurate (both more sensitive and specific) than non-contrast MR angiography for the diagnosis of vascular stenoses, and similar to conventional angiography for the overall characterization of vascular disease, without the need for catheterization." 01/01/2008 - "Prior to approval, gadofosveset underwent extensive testing to evaluate the safety and efficacy of the drug; the clinical trials show that gadofosveset-enhanced magnetic resonance angiography (MRA) is safe and well tolerated in patients with vascular disease and effective for the detection of vascular stenosis and aneurysms gadofosveset has the potential to open new horizons in diagnostic MRA by increasing the spatial resolution and the robustness of MRA examinations and facilitating the examination of multiple vascular beds." 09/01/2010 - "Twelve patients with nonshrinking aneurysms but no evidence of endoleak on CT angiography and delayed CT underwent MRI with a blood pool contrast agent (Gadofosveset trisodium, Bayer Schering Pharma, Berlin, Germany). "
4.	Rectal Neoplasms (Rectal Cancer) 03/01/2011 - "This study shows high reproducibility and significantly improved accuracy compared to standard MRI for gadofosveset-enhanced MRI for nodal staging and restaging in rectal cancer." 02/01/2014 - "Performance of gadofosveset-enhanced MRI for staging rectal cancer nodes: can the initial promising results be reproduced?" 02/01/2014 - "The aim of this study was to prospectively confirm the diagnostic performance of gadofosveset MRI for nodal (re)staging in rectal cancer in a second patient cohort. " 03/01/2011 - "This study aims to assess the accuracy of MRI using a novel lymph node magnetic resonance contrast, gadofosveset, for nodal staging and restaging in rectal cancer using a per node comparison with histology as the reference standard. " 08/01/2014 - "Value of gadofosveset-enhanced MRI and multiplanar reformatting for selecting good responders after chemoradiation for rectal cancer."
5.	Peripheral Vascular Diseases (Peripheral Vascular Disease) 07/01/2005 - "On the basis of substantial improvements over non-contrast MR angiography in efficacy and a minimal and transient side-effect profile, gadofosveset was found to be safe and effective for MR angiography in patients known or suspected to have peripheral vascular disease." 07/01/2005 - "Aortoiliac occlusive disease in patients with known or suspected peripheral vascular disease: safety and efficacy of gadofosveset-enhanced MR angiography--multicenter comparative phase III study." 01/01/2004 - "These trials were initiated in accordance with the recommendations of the FDA to expand gadofosveset's target indication of aortoiliac occlusive disease to a broader peripheral vascular disease indication. " 12/01/2003 - "MR angiography with gadofosveset trisodium for peripheral vascular disease: phase II trial." 06/01/2013 - "The purpose of this review is to illustrate various applications of gadofosveset trisodium in evaluating abdominal and peripheral vascular disease. "

Related Drugs and Biologics

1.	Contrast Media
2.	gadofosveset trisodium (MS 325)
3.	Gadolinium
4.	Antigens
5.	Albumins
6.	Gadolinium DTPA (Magnevist)
7.	gadobutrol
8.	Biomarkers (Surrogate Marker)
9.	Apolipoproteins E (ApoE)
10.	Warfarin (Coumadin)

Related Therapies and Procedures

1.	Endovascular Aneurysm Repair
2.	Therapeutics
3.	Intravenous Administration
4.	Chemoradiotherapy
5.	Catheters